What were Edible Garden’s (NASDAQ:EDBL) total revenues for Q1 2026?

Edible Garden reported total revenue of approximately $3.3 million for Q1 2026, representing a 22.9% increase from $2.7 million in Q1 2025. Growth was driven by retail expansion and broader consumer adoption of its product portfolio.

Which product categories contributed most to Edible Garden’s Q1 2026 revenue growth?

Fresh-cut herb sales surged 46% year-over-year due to new account integrations at Kroger and Weis Markets. Vitamin and supplement sales increased 27%, while branded condiments grew 51%, collectively driving top-line growth.

How did operational expenses impact Edible Garden’s profitability in Q1 2026?

Total operating expenses rose 77.5% year-over-year to $10 million, primarily due to higher production costs and a $2.5 million increase in depreciation from retooling facilities for the new beverage operations. These expenses weighed on near-term profitability.

What was Edible Garden’s net income and EPS in Q1 2026?

The company posted a net loss of $3.7 million, compared to a net loss of $3.3 million a year ago. Due to equity restructuring, net loss per share improved significantly to ($5.25) per common share from ($24.74) in Q1 2025.

Edible Garden revenue rises 23% as company accelerates shift to RTD nutrition

Q: How did one-time tax benefits affect Edible Garden’s Q1 2026 results?

Edible Garden recorded a $3.4 million income tax benefit from the sale of unutilized state tax credits under the New Jersey Economic Development Authority’s corporate tax certificate program. This partially cushioned the net loss for the quarter.

Written by Isaac FrancisPublished May. 16 2026Last Updated May. 15 2026

Edible Garden (NASDAQ:EDBL) reported strong top-line revenue growth for the first quarter of 2026, driven by retail expansion and broader consumer adoption of its product portfolio, even as heavy capital deployment for its beverage infrastructure weighed on near-term profitability.

The Belvidere, New Jersey-based controlled environment agriculture (CEA) specialist generated total revenue of approximately $3.3 million for the three months ended March 31, 2026, representing a 22.9% increase compared to the $2.7 million recorded in the first quarter of 2025.

The top-line advancement was anchored by a 46% year-over-year surge in fresh-cut herb sales following new account integration at Kroger and Weis Markets, alongside a 27% increase in vitamin and supplement sales and a 51% jump in branded condiments.

However, the company’s ongoing transition toward a diversified, shelf-stable consumer packaged goods footprint introduced sharp operational headwinds.

Total operating expenses rose 77.5% year-over-year to $10 million, up from $5.6 million in the prior year's opening period.

The surge in overhead was primarily driven by higher production costs and a $2.5 million increase in depreciation expense tied to the accelerated depreciation of legacy assets as the company retools facilities for its new beverage operations.

As a result of the infrastructure write-downs and a negative gross profit margin during the build-out phase, Edible Garden posted a net loss of $3.7 million for the quarter, compared to a net loss of $3.3 million a year earlier.

Because of equity restructuring, the net loss per share optimized significantly to ($5.25) per common share, improving from a loss of ($24.74) per share in the first quarter of 2025.

The quarterly financial impact was cushioned by a $3.4 million income tax benefit realized through the sale of unutilized state tax benefits under the New Jersey Economic Development Authority’s corporate tax certificate program.

Operationally, management prioritized the physical build-out of its new Midwest Ready-to-Drink (RTD) nutrition platform at its Prairie Hills hub in Webster City, Iowa.

The facility, a former aquaculture center being converted into a functional beverage site, advanced its integration of advanced Tetra Pak processing and high-speed aseptic packaging lines.

The infrastructure is configured to handle contract manufacturing and proprietary functional formulations aimed at the GLP-1 support and active lifestyle consumer verticals, with commercial production capabilities scaling through the second half of the fiscal year.